Octreotide (Sandostatin, Mycapssa)
Synthetic somatostatin analog used in acromegaly, neuroendocrine tumors, and selected GI conditions.
At a glance
What it is: Synthetic somatostatin analog used in acromegaly, neuroendocrine tumors, and selected GI conditions..
Primary research applications:
- Acromegaly
- Neuroendocrine tumors (carcinoid, VIPoma)
- Variceal bleeding
- Severe diarrhea in select conditions
Editorial summary: Octreotide is one of the longest-running, FDA-approved therapeutic peptides — a cornerstone of acromegaly and neuroendocrine tumor management since 1988. It is the prototypical "successful peptide drug" and a frequent reference point in any discussion of peptide therapeutics.
- Class / structure
- Synthetic octapeptide; somatostatin analog
- Half-life
- ≈ 90 minutes (immediate release); long-acting depot formulations available
- First described
- 1980 (Bauer et al.)
- Regulatory status
- FDA-approved (1988)
What is Octreotide?
Octreotide is a synthetic eight-amino-acid analog of somatostatin engineered for stability and selective somatostatin receptor subtype binding (preferentially SSTR2 and SSTR5).
Discovery and development
Octreotide was synthesized at Sandoz (now Novartis) by Bauer and colleagues in 1980. As a stable, long-acting somatostatin analog, it solved the problem that endogenous somatostatin's plasma half-life is too short (less than 3 minutes) for therapeutic use. The molecule was approved by the FDA in 1988 for symptomatic management of carcinoid and VIPoma syndromes, with subsequent label expansion to acromegaly and other indications. The oral formulation Mycapssa (2020) was a notable later addition.
Mechanism of action
Octreotide binds somatostatin receptors expressed on pituitary somatotrophs (suppressing GH release), neuroendocrine tumor cells (suppressing hormone secretion), and various other tissues. The pharmacology overlaps endogenous somatostatin but with much longer duration of action and receptor-subtype selectivity.[1]
Pharmacokinetics
Immediate-release octreotide has a plasma half-life of ~90 minutes, supporting two-to-three times daily subcutaneous dosing. Long-acting release (LAR) formulations support monthly intramuscular injection. Mycapssa is the oral formulation enabled by sodium caprylate excipient absorption enhancement.
What the research shows
The peer-reviewed literature on Octreotide is summarized below across two tiers: human research (the highest standard), and preclinical / emerging research (animal models and early-stage human work).
Claims and the evidence behind them
This table summarizes commonly discussed claims and how the published evidence weighs in. The aim is clarity — supported claims, claims that look promising but need more data, and claims that outrun the science.
| Claim | What the evidence shows | Verdict |
|---|---|---|
| Treats acromegaly effectively | Decades of clinical evidence | Supported |
| Controls neuroendocrine tumor symptoms | PROMID and other RCTs | Supported |
| Slows neuroendocrine tumor progression | PROMID — supported | Supported |
Reported user experiences
How the research describes administration
Subcutaneous injection (immediate release), monthly intramuscular injection (LAR depot), or oral capsule (Mycapssa). All are clinical formulations administered under medical supervision.
Editorial note
Administration details above describe how the peptide is given in published studies. We summarize this for educational completeness — these descriptions are not protocols, dosing recommendations, or instructions for personal use. Decisions about treatment require an appropriately licensed clinician.
Safety considerations and open questions
The takeaway
Octreotide is one of the foundational therapeutic peptides — a clean illustration that peptide drugs can be transformative when target biology, molecular design, and delivery come together. Its multi-decade clinical track record makes it a durable reference point in peptide pharmacology and a reminder that the peptide-therapeutics field includes well-validated, life-changing drugs alongside more speculative agents.
Frequently asked questions
What is octreotide used for?
Acromegaly, symptomatic management of carcinoid and VIPoma syndromes, control of neuroendocrine tumor progression in well-differentiated tumors, and adjunctive control of acute variceal bleeding.
Is octreotide the same as somatostatin?
It is a synthetic analog with similar but receptor-selective activity. Endogenous somatostatin is too short-acting for therapeutic use.
References
- Lamberts SW, van der Lely AJ, de Herder WW, Hofland LJ. Octreotide. N Engl J Med. 1996;334(4):246-254. https://pubmed.ncbi.nlm.nih.gov/8532003/
- Melmed S, et al. A consensus statement on acromegaly therapeutic outcomes. Nat Rev Endocrinol. 2018;14(9):552-561. https://pubmed.ncbi.nlm.nih.gov/30050156/